Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jimu Granules
- Development stage
- Unknown
- Lead developer
- Beijing White Flower Loropetalum Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jimu Granules is a Traditional Chinese Medicine (TCM) candidate developed by Beijing White Flower Loropetalum Biotechnology Co., Ltd. for the treatment of chronic non-atrophic gastritis. The drug is derived from the plant *Loropetalum chinense* (White Flower Loropetalum) and is specifically indicated for patients presenting with the "stomach heat and dampness" syndrome. It is thought to work by reducing gastric mucosal inflammation and providing cytoprotection. Jimu Granules has advanced to Phase 3 clinical trials in China, where its efficacy in relieving symptoms like epigastric pain and bloating is being compared against standard care or placebo.
- Brand names
- Jimu Granules
- Other names
- Jimu Keli棘木颗粒
Beyond the preview
Go deeper on Jimu Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jimu Granules.